124 related articles for article (PubMed ID: 12515379)
1. Bone disease in uremic patients: advances in PTH suppression.
Brancaccio D; Cozzolino M; Gorio A; Di Giulio AM; Gallieni M
J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
4. Management of secondary hyperparathyroidism.
Cunningham J
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S35-40. PubMed ID: 16109140
[TBL] [Abstract][Full Text] [Related]
5. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D3 polyunsaturated side-chain analogues (EB1089, GS1590) and the 20-epi-vitamin D3 analogue CB1393 suppress parathyroid hormone secretion and mRNA level in bovine parathyroid cells.
Segersten U; Holm PK; Binderup L; Akerström G; Hellman P; Westin G
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):289-94. PubMed ID: 15120422
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid growth and suppression in renal failure.
Lewin E; Huan J; Olgaard K
Semin Dial; 2006; 19(3):238-45. PubMed ID: 16689976
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D analogs as therapeutic agents: a clinical study update.
Wu-Wong JR; Tian J; Goltzman D
Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
[TBL] [Abstract][Full Text] [Related]
9. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
[TBL] [Abstract][Full Text] [Related]
10. [Renal failure and vitamin D].
Brown AJ; Dusso AS; Slatopolsky E
Clin Calcium; 2002 Jun; 12(6):711-23. PubMed ID: 15775356
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D physiology.
Lips P
Prog Biophys Mol Biol; 2006 Sep; 92(1):4-8. PubMed ID: 16563471
[TBL] [Abstract][Full Text] [Related]
12. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
13. New therapies for uremic secondary hyperparathyroidism.
Torres PU; Prié D; Beck L; Friedlander G
J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
[TBL] [Abstract][Full Text] [Related]
14. Strategies to minimize bone disease in renal failure.
Martin KJ; González EA
Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
Brown AJ; Slatopolsky E
Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
Brown AJ
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
[TBL] [Abstract][Full Text] [Related]
19. The role of phosphorus in the genesis of azotemic osteodystrophy.
Somerville PJ; Kaye M
Prog Biochem Pharmacol; 1980; 17():228-35. PubMed ID: 6894195
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
